本帖最后由 老马 于 2013-3-13 13:43 编辑
/ D! Y+ N' q. l' }
, `8 @0 G" f& w* n) E健择(吉西他滨)+顺铂+阿瓦斯汀
) H4 G+ L$ x% L& A Gemzar +Cisplatin + Avastin, O- f! {' `% ^$ W
http://annonc.oxfordjournals.org/content/21/9/1804.full
, b/ ~; Y0 u) E- i. ?Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) * U# C. D k: R5 [# B. N5 a6 L
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 2 L% y( y5 \+ d+ C2 |1 G! p
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
% S. ~& j2 v- Q! S. J
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 817)
0 y' u3 N! |4 Q0 K+ x' e! l3 f
华为网盘附件:- k2 n% d5 T; e
【华为网盘】ava.JPG1 M1 i" {. i0 G8 N6 a2 S
|